Open-label, Single-arm, Study Assessing the Efficacy and Safety of Ivabradine (Corlanor) in African-American/Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction
Phase of Trial: Phase IV
Latest Information Update: 02 Nov 2018
At a glance
- Drugs Ivabradine (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Sponsors Amgen
- 16 Jul 2018 Planned End Date changed from 23 Sep 2018 to 11 Mar 2019.
- 16 Jul 2018 Planned primary completion date changed from 23 Sep 2018 to 11 Mar 2019.
- 09 Mar 2018 New trial record